Cadrenal Therapeutics, Inc. — Director's Dealing 2025

Oct 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cadrenal Therapeutics, Inc. (CVKD)
CIK: 0001937993
Period of Report: 2025-10-24

Reporting Person: Pham Quang X (Director, CEO and Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-24	Common Stock	S	1129	$14.03	Disposed	197404	Direct
2025-10-27	Common Stock	S	1315	$13.99	Disposed	196089	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	200000	Indirect

Footnotes

F1: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.